Atezolizumab

A4DAB026 | Cancer | Approved
PDL1/CD274
G1 / IgG1
Amgen ARCAGY/GINECO Group BioLineRx Chugai Pharmaceutical Clovis Oncology Dana-Farber Cancer Institute Duke University European Organisation for Research and Treatment of Cancer Exelixis Fondazione Michelangelo GEICO (Spanish Ovarian Cancer Research Group) Genentech GERCOR Gradalis H. Lee Moffitt Cancer Center and Research Institute Immune Design Incyte Corporation Johns Hopkins University Kaiser Permanente M. D. Anderson Cancer Center Memorial Sloan-Kettering Cancer Center National Cancer Center (Korea) National Cancer Institute (USA) Netherlands Cancer Institute Roche Sanofi Seattle Genetics University Hospital Southampton NHS Foundation Trust University Medical Center Groningen University of California University of California at San Francisco University of Oklahoma Yale University
Approved
Whole mAb
MPDL-3280A MPDL3280A RG-7446 RG7446 RG7446-42 RO-5541267 RO5541267 TECENTRIQ
5.8
Avg A4D Score
-0.6556
Score Range
-0.68 to -0.62
Structures
6
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB026_5xxy_H_L 5xxy 99% -0.6532 6.5 4.0 -0.1812 -0.71
A4DAB026_5x8l_H_M 5x8l 100% -0.6156 6.5 4.0 -0.1601 -0.6695
A4DAB026_5x8l_S_N 5x8l 100% -0.6674 6.5 4.0 -0.2012 -0.7241
A4DAB026_5x8l_J_O 5x8l 100% -0.6449 7.0 4.0 -0.2084 -0.6971
A4DAB026_5x8l_F_K 5x8l 100% -0.6838 6.5 4.0 -0.2015 -0.7409
A4DAB026_5x8l_G_L 5x8l 100% -0.669 6.5 4.0 -0.2149 -0.7246